NEW DELHI: Intas Pharmaceuticals has launched its first biosimilar product, Accofil, used in treating immune system disorders, in European markets. The company has launched its first biosimilar, ...

Approval has been recommended for 2 new generic drugs that can be used in cancer treatment in the European Union, as has an expanded indication for a third drug. Busulfan Fresenius Kabi is a generic ...

The product has recently been introduced under the brand Accofil Intas Pharmaceuticals has launched their first biosimilar, filgrastim, in Europe, through their wholly-owned subsidiary Accord ...

At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop. “Reliance Life ...